Why carry out this study? |
There is currently no direct head-to-head evidence of the long-term efficacy of bimekizumab compared to other interleukin (IL)-17A inhibitors in psoriatic arthritis (PsA) |
This study uses matching-adjusted indirect comparisons (MAICs) to compare the efficacy of bimekizumab 160 mg every 4 weeks (Q4W) and secukinumab 150 mg and 300 mg Q4W at 52 weeks for the treatment of PsA in patients who were naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD-naïve) or patients who have previous inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors (TNFi-IR) |
What was learned from this study? |
In patients who were bDMARD-naïve, bimekizumab had a greater likelihood of achieving at least a 70% improvement according to American College of Rheumatology response criteria (ACR70) outcome compared to secukinumab 150 mg and secukinumab 300 mg at 52 weeks |
In patients who were TNFi-IR, bimekizumab had a greater likelihood of response compared to secukinumab 150 mg for ACR20, ACR70, and minimal disease activity (MDA) outcomes and a greater likelihood of response compared to secukinumab 300 mg for ACR50 and MDA outcomes at 52 weeks |
Bimekizumab can be considered as more effective than, or at least comparable to, secukinumab in achieving long-term, positive treatment outcomes in PsA |
Introduction
Methods
Systematic Literature Review and Source Data
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.
Selection of Baseline Characteristics for Matching
Adjustment of IPD to Aggregate Data and Pairwise Comparisons
Outcomes
Reporting of Missing Data
Non-Placebo-Adjusted Outcome Comparisons
Reporting of Results
Results
Mean ± SD unless stated | bDMARD-naïve | TNFi-IR | ||
---|---|---|---|---|
BE OPTIMAL | FUTURE 2a bDMARD-naïve | BE COMPLETE/BE VITAL | FUTURE 2a TNFi-IR | |
N = 431 | N = 63 (150 mg) N = 67 (300 mg) | N = 267 | N = 33 (150 mg) N = 37 (300 mg) | |
Age, years | 49 (13) | 47 (12) | 50 (12) | 48 (12) |
Male, % | 47 | 51 | 49 | 52 |
MTX use, % | 59 | 49 | 45 | 40 |
SJC (of 66 joints) | 9.0 (6.2) | 10.8 (8.6) | 9.7 (7.5) | 12.4 (9.7) |
TJC (of 68 joints) | 16.8 (11.8) | 20.3 (14.7) | 18.4 (13.5) | 25.6 (19.1) |
HAQ-DI score | 0.82 (0.59) | 1.2 (0.6) | 0.97 (0.59) | 1.3 (0.6) |
BSA ≥ 3%, % | 50 | 51 | 66 | 48 |